CNBC's Huckman On JAMA/Plavix Study
By: Mark Koba | Senior Editor, CNBC
Bristol-Myers got some good news Tuesday afternoon-- and CNBC's Mike Huckman had the story. A new report from the Journal of the American Medical Association says long term use of Plavix--reduces significant health risks.
The JAMA report says that if patients stay on Plavix for two years--the drug will greatly reduce or eliminate heart attacks. The FDA say patients with drug coated implanted stents should take Plavix for up to 6 months after certain stents are implanted.
Plavix is the largest selling biggest pharmaceutical drug for Bristol-Meyers. It's a blood thinner. It has seen some sales declines recently due to a generic competitors.
Bristol-Myers got some good news Tuesday afternoon-- and CNBC's Mike Huckman had the story. A new report from the Journal of the American Medical Association says long term use of Plavix--reduces significant health risks. The JAMA report says that if patients stay on Plavix for two years--the drug will greatly reduce or eliminate heart attacks.
